COMPANY PROFILE

N-Power Medicine

Explore full profile

Accelerating oncology innovation with faster drug development and better therapy outcomes

Redwood City, United StatesFounded 2021Health

Valuation $100–250M Last recorded · 2026

Headcount 100–500 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About N-Power Medicine

N Power Medicine operates in the healthcare sector, specifically focusing on oncology, which is the study and treatment of cancer. The company aims to accelerate the development of cancer therapies, thereby improving patient outcomes. By leveraging advanced technologies and innovative methodologies, N Power Medicine seeks to shorten the drug development timeline, making effective treatments available more quickly. The primary clients are pharmaceutical companies and healthcare providers who are involved in cancer treatment and research. The market it operates in is highly specialized and competitive, with a focus on cutting-edge medical research and drug development. The business model revolves around partnerships and collaborations with pharmaceutical firms and research institutions, generating revenue through service fees, research grants, and possibly licensing agreements for their proprietary technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Redwood City, United States
Employees: 113
Open positions: 7
Dealroom signal: 70.9/100
Industry: Health
Sector: Health, Biotechnology, Oncology, Drug Development, Biotech and Pharma
Client focus: b2b
Investment activity: 1 company, latest Jan 2025
Capital deployed: —
Preferred round: ACQUISITION
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Sep 2026	$32M	$128M	Merck Global Health Innovation Fund · Innovatus Capital Partners	↗
SERIES B✓Equity / VC	Jul 2024	$0	—	Merck Global Health Innovation Fund	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

N-Power Medicine website traffic

Latest recorded traffic for N-Power Medicine is 1.9K monthly website visits, up 46.2% over the last three months. N-Power Medicine's team declined 4.2% over the past year.

Latest monthly visits1.9K 3-month web change+46.2% 1-year team growth-4.2%

Monthly website visitsJun 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Contracts & Legal OperationsRedwood City, CA · Legal · Sep 3, 2026 Director, Pharma Delivery OperationsRedwood City, California, United States, Northern America, Americas · Human Resources · Aug 11, 2026 Associate Director, Clinical OperationsRedwood City, CA · Other · Aug 4, 2026 Clinical Research Coordinator/DHS II - Albuquerque, NM 7.21.2026Albuquerque, NM · Other · Jul 27, 2026 Staff, Product Development LifecycleRedwood City, CA · Business Development · Jul 16, 2026 Human Resources CoordinatorRedwood City, CA · Human Resources · Jun 30, 2026 Human Resources CoordinatorSan Francisco Bay Area · Human Resources · Jun 26, 2026

7 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAdoram TherapeuticsInnovative immunotherapies targeting solid tumors using allosteric biochemistry	Lancy, Switzerland	Operational	—	$2.6M	$11M
ATAi TherapeuticsAI Therapeutics - Deep Learning Precision Medicine	Guilford, United States	Acquired
MEMEDICStreamlined cancer drug target discovery/validation by CRISPR functional genomics in cancer organoid models at scale	Mountain View, United States	Operational
TTTargTex TherapeuticsTargeted therapies for the treatment of brain cancer. TargTex SA is a portuguese biotech company founded in 2019	Torres Vedras, Portugal	Operational
OTOdyssey TherapeuticsBuilding a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases	Boston, United States	Operational
BMBeOne MedicinesInnovative oncology therapeutics for global cancer care accessibility, formerly BeiGene	Dongcheng District, China	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational